Slone Partners

People Are Our Science®
www.slonepartners.com

This is very exciting news!

Parabilis Medicines has achieved the biggest Nasdaq debut ever for the biopharma industry! The funding from this IPO will help fast track the company’s development of a new treatment for desmoid tumors and highlights continued investor confidence in innovative science with the potential to transform patient care.

Congratulations to the Parabilis team on this milestone—and to the biotech community on another encouraging sign for the sector's future!

Parabilis' $670M IPO sets new biotech record, will fund cancer drug Parabilis Medicines prices a $670M IPO — the biggest biotech Nasdaq debut ever — to fund its experimental desmoid-tumor drug zolucatetide.

Venture-backed life sciences companies move fast—your leadership strategy has to move faster.

We partner with venture capital firms and their life sciences portfolio companies to identify and place the executives who can scale innovation, navigate inflection points, and deliver results.

From early-stage builds to growth acceleration, we bring the leadership that drives what’s next.

Explore how we support venture-backed organizations: https://www.slonepartners.com/venture-capital-recruiting/